Mitochondrial ROS Induce Partial Dedifferentiation of Human Mesothelioma via Upregulation of NANOG.
mesothelioma
mitochondria
pluripotency factors
reactive oxygen species
reprogramming
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
received:
29
06
2020
accepted:
08
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
16
7
2020
Statut:
epublish
Résumé
The expression of pluripotency factors is a key regulator of tumor differentiation status and cancer stem cells. The purpose of this study was to examine the expression of pluripotency factors and differentiation status of human mesothelioma and the role of mitochondria in their regulation. We tested the expression of OCT4/
Identifiants
pubmed: 32664372
pii: antiox9070606
doi: 10.3390/antiox9070606
pmc: PMC7402173
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hrvatska Zaklada za Znanost
ID : IP-2014-09-4173
Références
Am J Cancer Res. 2013 Jun 20;3(3):312-22
pubmed: 23841030
Int J Biochem Cell Biol. 2014 Sep;54:174-85
pubmed: 25084555
Integr Biol (Camb). 2019 Feb 26;:
pubmed: 30809641
Onco Targets Ther. 2018 Sep 06;11:5515-5526
pubmed: 30233213
Cancer Cell. 2003 Oct;4(4):257-62
pubmed: 14585353
Asian Pac J Cancer Prev. 2013;14(6):3625-30
pubmed: 23886156
Nat Genet. 2008 May;40(5):499-507
pubmed: 18443585
Oncotarget. 2016 May 3;7(18):25113-24
pubmed: 26848621
Mol Cell. 2012 Nov 30;48(4):627-40
pubmed: 23041284
Cell Transplant. 2012;21(11):2523-30
pubmed: 22863088
Stem Cells. 2010 Dec;28(12):2141-50
pubmed: 20945330
J Vis Exp. 2018 May 20;(135):
pubmed: 29863662
Arch Pharm Res. 2010 Jul;33(7):1117-25
pubmed: 20661723
BMC Cancer. 2018 Aug 15;18(1):819
pubmed: 30111297
Sci Rep. 2016 Apr 15;6:24578
pubmed: 27080907
Trends Mol Med. 2020 Feb;26(2):185-200
pubmed: 31679988
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Biol Chem. 2017 Sep 26;398(10):1095-1108
pubmed: 28384098
Am J Physiol Cell Physiol. 2010 Aug;299(2):C506-15
pubmed: 20519447
Adv Cancer Res. 2014;122:1-67
pubmed: 24974178
Cancer Gene Ther. 2015 Aug;22(8):387-95
pubmed: 26206198
Lung Cancer. 2012 Jul;77(1):192-8
pubmed: 22459204
Pharmacol Res. 2019 Jan;139:298-313
pubmed: 30453033
BMC Cancer. 2010 Feb 22;10:54
pubmed: 20175889
Int J Cancer. 2017 Oct 1;141(7):1402-1412
pubmed: 28614911
Redox Biol. 2017 Oct;13:235-243
pubmed: 28595161
Histol Histopathol. 2018 Sep;33(9):995-1004
pubmed: 29722422
Expert Rev Proteomics. 2017 Nov;14(11):1037-1053
pubmed: 28974114
Med Oncol. 2015 Jan;32(1):433
pubmed: 25491144
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
J Cell Physiol. 2017 Jan;232(1):216-24
pubmed: 27138089
Cancer Res. 2011 Jul 1;71(13):4640-52
pubmed: 21712410
Stem Cells. 2015 Aug;33(8):2381-90
pubmed: 25821200
Nat Rev Genet. 2012 Mar 13;13(4):227-32
pubmed: 22411467
Stem Cells. 2012 May;30(5):876-87
pubmed: 22311737
Anesthesiology. 2010 Oct;113(4):906-16
pubmed: 20823757
Oncol Rep. 2017 Apr;37(4):2252-2260
pubmed: 28260004
J Adv Res. 2018 Jun 01;14:73-79
pubmed: 30023134
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Stem Cell Reports. 2017 Apr 11;8(4):1005-1017
pubmed: 28285878
Cell Metab. 2015 Jan 6;21(1):81-94
pubmed: 25565207
Breast Cancer. 2017 Mar;24(2):326-335
pubmed: 27300169
J Immunol Methods. 2008 Feb 29;331(1-2):140-6
pubmed: 18234207
J Surg Res. 2012 May 1;174(1):130-5
pubmed: 21227461
Oncogene. 2018 Dec;37(49):6357-6367
pubmed: 30061637
BMC Cancer. 2015 Oct 15;15:698
pubmed: 26472348
Cancer Cell. 2012 Mar 20;21(3):283-96
pubmed: 22439924
J Oral Pathol Med. 2011 Sep;40(8):621-8
pubmed: 21342274
Med Sci Monit. 2019 Oct 31;25:8172-8180
pubmed: 31670317
Anesthesiology. 2012 Oct;117(4):735-44
pubmed: 22820846
Stem Cells. 2011 Mar;29(3):486-95
pubmed: 21425411
J Neurochem. 2003 Sep;86(5):1101-7
pubmed: 12911618
Int J Oncol. 2011 Nov;39(5):1285-94
pubmed: 21837363
Biotechniques. 2016 May 01;60(5):229-38
pubmed: 27177815